Article

Higher Dose of Fulvestrant Associated With Improved Survival in Advanced Breast Cancer

Author(s):

Ben Leach

Postmenopausal women with advanced estrogen receptor–positive breast cancer lived longer when they received a 500-mg dose of fulvestrant as compared with a 250-mg dose.

Postmenopausal women with advanced estrogen receptor–positive breast cancer lived longer when they received a 500-mg dose of fulvestrant as compared with a 250-mg dose.

Click here to view this article.

Related Videos
3 experts are featured in this series.
Pranav Garimella, MBBS, MPH | Credit: GlobalNewsWire
3 experts are featured in this series.
3 experts are featured in this series.
Related Content
Michael E. Thase, MD I Credit: Perelman School of Medicine
February 3rd 2025

GH001 Achieves Significant Depression Symptom Reduction in Phase 2b Trial

Chelsie Derman
Skin of Color Savvy: Pigmentary Disorders in Skin of Color, with Nada Elbuluk, MD, and Michelle Rodrigues, MBBS
February 3rd 2025

Skin of Color Savvy: Pigmentary Disorders in Skin of Color, with Nada Elbuluk, MD, MSc, and Michelle Rodrigues, MBBS

HCPLive Rheumatology Month in Review
February 3rd 2025

Rheumatology Month in Review: January 2025

Victoria Johnson
Diabetes Dialogue: Understanding Semaglutide (Ozempic) in CKD and T2D
January 31st 2025

Diabetes Dialogue: Understanding Semaglutide (Ozempic) in CKD and T2D

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
Tamara N. Kimball, MD I Credit: Massachusetts General Hospital, Center for Neurotechnology and Neurorecovery
February 3rd 2025

Shorter Telomere Length Linked to Increased Risk of Stroke, Dementia, Depression

Chelsie Derman
Study Highlights Success of Upadacitinib for Atopic Dermatitis in Various Clinical Phenotypes
February 3rd 2025

Study Highlights Success of Upadacitinib for Atopic Dermatitis in Various Clinical Phenotypes

Tim Smith
© 2025 MJH Life Sciences

All rights reserved.